Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH3 known ✓ | Q9ULD8 | 1/20 | 0.49 |
| ▸ | CACNA2D1 known ✓ | P54289 | 3/20 | 0.44 |
| ▸ | RAC1 | P63000 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | DOT1L | Q8TEK3 | 6/20 | 0.60 |
| ▸ | TERT | O14746 | 7/20 | 0.49 |
| ▸ | CCR4 | P51679 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2639296 | 0.99 | RAC1 (0.98) | RAC1MAPTDOT1LKCNH3TERT | |
| SCHEMBL13868216 | 0.89 | RAC1 (0.81) | RAC1MAPTDOT1LKCNH3TERT | |
| SCHEMBL14825396 | 0.89 | RAC1 (0.80) | RAC1MAPTDOT1LTERT | |
| SCHEMBL3389936 | 0.88 | RAC1 (0.79) | RAC1MAPTDOT1LKCNH3CACNA2D1 | |
| Ammonia Solution, Strong SCHEMBL3727545 | 0.81 | RAC1 (0.69) | RAC1MAPTKCNH3CACNA2D1CCR4 | |
| SCHEMBL3389537 | 0.81 | RAC1 (0.68) | RAC1MAPTKCNH3TERTCACNA2D1 | |
| Hydrochloric Acid SCHEMBL17022810 | 0.78 | RAC1 (0.64) | RAC1MAPTDOT1LTERTCCR4 | |
| SCHEMBL2639299 | 0.77 | RAC1 (0.63) | RAC1MAPTDOT1LTERTCCR4 | |
| SCHEMBL3392632 | 0.74 | RAC1 (0.58) | RAC1MAPTKCNH3CACNA2D1CCR4 | |
| Hydrochloric Acid SCHEMBL23242210 | 0.72 | RAC1 (0.56) | RAC1MAPTKCNH3CACNA2D1CCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12569494-B2 | Compositions and methods to promote thymic regeneration | FRED HUTCHINSON CANCER CENTER (US) | 2026-03-10 | — | — | US | disclosed |
| EP-4630014-A1 | METHOD FOR OPTIMIZING T CELLS FOR IMMUNO-THERAPY | CeMM - Forschungszentrum für Molekulare Medizin GmbH (AT) | 2025-10-15 | — | — | EP | disclosed |
| EP-4619518-A1 | METHOD OF MODIFYING CELLS | Royal Melbourne Institute of Technology (AU) | 2025-09-24 | — | — | EP | disclosed |
| US-20250249014-A1 | A COMBINATION FOR TREATING A RETINAL DISEASE | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2025-08-07 | — | — | US | disclosed |
| EP-4582448-A2 | S100 PROTEINS AS NOVEL THERAPEUTIC TARGETS IN MYELOPROLIFERATIVE NEOPLASMS | Erasmus University Rotterdam Medical Center (NL) | 2025-07-09 | — | — | EP | disclosed |
| EP-4558141-A1 | A COMBINATION FOR TREATING A RETINAL DISEASE | Hadasit Medical Research Services&Development Ltd. (IL) | 2025-05-28 | — | — | EP | disclosed |
| WO-2024261302-A1 | NLRP3 INHIBITORS, PAK1/2 INHIBITORS AND/OR CASPASE 1 INHIBITORS FOR USE IN THE TREATMENT OF RAC2 MONOGENIC DISORDERS | Institut National de la Santé et de la Recherche Médicale (FR) | 2024-12-26 | — | — | WO | disclosed |
| US-20240400983-A1 | CELL AGGREGATE INCLUDING PITUITARY HORMONE-PRODUCING CELLS AND METHOD FOR PRODUCING SAME | Sumitomo Pharma Co., Ltd. (JP) | 2024-12-05 | — | — | US | disclosed |
| US-20240392241-A1 | METHOD FOR PRODUCING CELL MASS INCLUDING PITUITARY TISSUE AND CELL MASS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2024-11-28 | — | — | US | disclosed |
| EP-4410963-A1 | METHOD FOR PRODUCING CELL MASS INCLUDING PITUITARY TISSUE AND CELL MASS | Sumitomo Chemical Company, Limited (JP) | 2024-08-07 | — | — | EP | disclosed |
| EP-3740208-A1 | COMPOUNDS FOR TREATING RAC-GTPASE MEDIATED DISORDER | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2020-11-25 | — | — | EP | disclosed |
| US-20200347044-A1 | Compounds for Treating Rac-GTPase Mediated Disorder | CHILDREN'S MEDICAL CENTER CORPORATION | 2020-11-05 | — | — | US | disclosed |
| US-20200331901-A1 | Compounds for Treating Rac-GTPase Mediated Disorder | CHILDREN'S MEDICAL CENTER CORPORATION | 2020-10-22 | — | — | US | disclosed |
| US-10774075-B2 | Compounds for treating rac-GTPase mediated disorder | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2020-09-15 | — | — | US | disclosed |
| EP-3286184-B1 | COMPOUNDS FOR TREATING RAC-GTPASE MEDIATED DISORDER | CHILDRENS MEDICAL CENTER (US) | 2020-03-25 | — | — | EP | disclosed |
| WO-2019143833-A1 | COMPOUNDS FOR TREATING RAC-GTPASE MEDIATED DISORDER | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2019-07-25 | — | — | WO | disclosed |
| US-20180134694-A1 | Compounds for Treating Rac-GTPase Mediated Disorder | CHILDREN'S MEDICAL CENTER CORPORATION | 2018-05-17 | — | — | US | disclosed |
| US-20150265608-A1 | Compounds for Treating Rac-GTPase Mediated Disorder | CHILDREN'S MEDICAL CENTER CORPORATION | 2015-09-24 | — | — | US | disclosed |
| EP-2908813-A1 | COMPOUNDS FOR TREATING RAC-GTPASE MEDIATED DISORDER | Children's Medical Center Corporation (US) | 2015-08-26 | — | — | EP | disclosed |
| US-20100272706-A1 | ANTIVIRALS | MERCER JASON | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250249014-A1 | A COMBINATION FOR TREATING A RETINAL DISEASE | ALDH1A2, NR2E3, EYA3 | KCNH3 4289/4885CACNA2D1 4038/4885RAC1 250/4885 |
| US-20200347044-A1 | Compounds for Treating Rac-GTPase Mediated Disorder | ARHGDIB, ARHGEF2, ARHGDIA | KCNH3 4727/4885CACNA2D1 2787/4885RAC1 4/4885 |
| US-20180134694-A1 | Compounds for Treating Rac-GTPase Mediated Disorder | ARHGEF2, ARHGDIB, CDC42 | KCNH3 4689/4885CACNA2D1 2913/4885RAC1 6/4885 |
| US-12569494-B2 | Compositions and methods to promote thymic regeneration | CDC42, BMP4, TPMT | KCNH3 4730/4885CACNA2D1 2249/4885RAC1 105/4885 |
| US-10774075-B2 | Compounds for treating rac-GTPase mediated disorder | ARHGEF2, ARHGDIB, CDC42 | KCNH3 4689/4885CACNA2D1 2913/4885RAC1 6/4885 |
| US-20150265608-A1 | Compounds for Treating Rac-GTPase Mediated Disorder | ARHGEF2, ARHGDIB, ARHGDIA | KCNH3 4550/4885CACNA2D1 2978/4885RAC1 5/4885 |
| US-20200331901-A1 | Compounds for Treating Rac-GTPase Mediated Disorder | ARHGEF2, ARHGDIB, CDC42 | KCNH3 4689/4885CACNA2D1 2913/4885RAC1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.